The FDA may require weight-loss drugs to undergo clinical trials to see if they pose a risk of heart attack.
Advertisement
The Scientist
Most Recent
Once a promising cancer treatment, the failure of PARP inhibitors in the clinic may be due to flawed preclinical studies.
Two new cancer cell line databases bursting with genomic and drug profiling data may help researchers identify drug targets.
Check out the latest crop of high-resolution structures and how they inform biological function.
A new bill recently debated in the US Congress seeks to streamline the approval process for drugs.
Over the past 15 years, new laws and regulations in the United States and the European Union have expanded to require the inclusion of pediatric patients in clinical drug trials. Before these laws were enacted, the US Food and Drug Administration (F
Contributors
March 1, 2012
Meet some of the people featured in the March 2012 issue of The Scientist.
Two key pieces of legislation, enacted to spur drugmakers into testing pharmaceutical products in children, are up for reauthorization in the US Congress this October. Have they done their jobs?
A lot changes in a child’s body over the course of development, and not all changes occur linearly: gene expression can fluctuate, and organs can perform different functions on the way to their final purpose in the body. Here are some of the key deve
The Pediatric Research Equity Act (PREA) of 2003 requires that companies developing new drugs that could be used to treat a condition in children perform clinical trials in kids before winning FDA approval. The Best Pharmaceuticals for Children Act (
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
